Zymeworks (ZYME) Tax Provisions (2021 - 2026)
Zymeworks (ZYME) posted Tax Provisions of -$2.2 million for Q1 2026, down 711.48% sequentially from -$270000.0 in Q4 2025, and down 541.73% YoY from $496000.0 in Q1 2025.
Analysis
Zymeworks (ZYME) Tax Provisions (2021 - 2026) Analysis & Trends
Zymeworks has reported Tax Provisions for 6 years, with the latest figure at -$2.2 million in Q1 2026.
- Quarterly Tax Provisions fell 541.73% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 120.15% YoY) and the FY2025 annual result came in at $1.4 million, down 77.38% from the prior year.
- Tax Provisions eased to -$2.2 million in Q1 2026 per ZYME's latest filing, from -$270000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $11.0 million in Q4 2022 and troughed at -$4.7 million in Q4 2023.
- A 5-year average of $917294.1 and a median of $75000.0 in 2024 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2023 and 2026: Tax Provisions surged 18477.78% in 2023, then slumped 541.73% in 2026.
- Over 5 years, Tax Provisions stood at $11.0 million in 2022, then sank by 142.91% to -$4.7 million in 2023, then surged by 221.03% to $5.7 million in 2024, then tumbled by 104.72% to -$270000.0 in 2025, then tumbled by 711.48% to -$2.2 million in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered -$2.2 million, -$270000.0, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Zymeworks | 2.15 Bn | 1.88 Bn | - | -273,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -273,000.00 |
| Mar 31, 2026 | -2.19 Mn |
| Dec 31, 2025 | -270,000.00 |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | -186,000.00 |
| Mar 31, 2025 | 496,000.00 |
| Dec 31, 2024 | 5.72 Mn |
| Sep 30, 2024 | 226,000.00 |
| Jun 30, 2024 | 68,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | -4.72 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | 1.65 Mn |
| Mar 31, 2023 | 1.39 Mn |
| Dec 31, 2022 | 11.01 Mn |
| Sep 30, 2022 | -29,000.00 |
| Jun 30, 2022 | -9,000.00 |
| Mar 31, 2022 | -74,000.00 |
| Dec 31, 2021 | -1.37 Mn |
| Sep 30, 2021 | 764,000.00 |